Chimeric antigen receptor (CAR) T cell therapy induces durable remissions in lymphoid malignancies, yet the extent and biology of long-term CAR T cell persistence in B cell lymphoma remain unclear. Here we report the persistence and characteristics of 4-1BB-costimulated anti-CD19 CAR T cells (CART19) up to 10 years aft...
L. Paruzzo, E. Chong, Elise A. Chong et al.· Nature Medicine· 0 citations
Ibrutinib improved proliferative fitness, attenuated senescence-associated features and SASP output in paired patient and direct-exposure assays, and enhanced CAR T-cell expansion in an ibrutinib-resistant CLL model.
Julia Han Noll, Devin Dersh, Jiang-Yuan Li et al.· Blood· 0 citations
Most molecularly characterized post-CAR T-cell lymphomas lack evidence of CAR vector-driven transformation and appear to reflect pre-existing or therapyselected clonal T-cell populations in the context of clonal hematopoiesis, immune dysregulation, and, in some cases, viral reactivation.
Federico Stella, J. Fraietta, S. Schuster et al.· Haematologica· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.